PRE vs LNTH vs CBLL Stock Comparison

Prenetics Global, Lantheus Holdings and Ceribell Prices as of Oct 27, 2026 Peers: Industry group
1 more company in this comparison (BFLY) Create a free account to keep reading and compare up to 10 companies.
PRE Prenetics Global Ltd
$18.43 -19.8% 1M +40.9% 1Y
Market cap
$310.99M
P/E
–
Revenue (TTM)
$185.92M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
LNTH Lantheus Holdings, Inc.
$100.15 +0.4% 1M +72.3% 1Y
Market cap
$6.54B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
6 wins
CBLL Ceribell, Inc.
$27.22 +14.9% 1M +111.2% 1Y
Market cap
$1.04B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

8 decided of 12

Lantheus Holdings leads on 6 of the 12 questions below (Lantheus Holdings 6, Prenetics Global 1, Ceribell 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPRELNTHCBLLLeader
Larger companyMarket capitalisation $310.99M $6.54B $1.04B LNTH
Cheaper on earningsLower P/E, profitable companies only -3.6x 23.7x -15.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 17.4x — –
Faster revenue growthRevenue growth, trailing twelve months +513.0% +2.3% +31.7% PRE
More profitableNet margin, trailing twelve months -38.2% 17.7% -64.7% LNTH
Better return on capitalReturn on invested capital — 12.5% — –
Less leveragedLower net debt / EBITDA — -0.1x 1.6x LNTH
Higher dividend yieldTrailing dividend yield 0.00% — — –
Better 1-year returnPrice return, last 12 months +40.9% +72.3% +111.2% CBLL
Better 5-year returnAnnualised price return, 5 years -30.7%/yr +34.4%/yr — LNTH
Less volatileAnnualised volatility, 1 year 81.0% 32.3% 52.1% LNTH
Higher overall scoreMean of the five percentile scores vs peers 51/100 80/100 38/100 LNTH

Percentile Scorecard

PRELNTHCBLL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPRELNTHCBLL
Valuation 35 #148 of 227 80 #46 of 227 22 #178 of 227
Growth 68 #70 of 219 63 #82 of 219 22 #172 of 219
Profitability 43 #118 of 206 94 #13 of 206 38 #129 of 206
Financial Health 57 #102 of 238 69 #74 of 238 81 #46 of 238
Shareholder Returns – 93 #11 of 134 30 #94 of 134
Overall 51 80 38
  • PRE ranked among 247 companies in Medical Devices and Diagnostics
  • LNTH ranked among 247 companies in Medical Devices and Diagnostics
  • CBLL ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPRELNTHCBLLSPY
1 month -19.8%+0.4%+14.9% -0.2%
3 months +0.9%-2.4%+52.7% +3.9%
6 months +0.3%+19.9%+30.9% +8.2%
Year to date +17.0%+50.5%+24.1% +12.9%
1 year +40.9%+72.3%+111.2% +12.3%
3 years +228.9%+49.9%— +87.4%
3 years, per year +48.8%+14.4%— +23.3%
5 years -84.0%+337.5%— +67.9%
5 years, per year -30.7%+34.4%— +10.9%
10 years —+1,092.3%— +261.1%
10 years, per year —+28.1%— +13.7%

Risk

MeasurePRELNTHCBLLSPY
Volatility, 1Y 81.0%32.3%52.1% 12.7%
Downside volatility, 1Y 74.2%27.5%49.5% 12.7%
Beta vs S&P 500, 1Y 1.520.591.21 1.00
Return / volatility, 1Y 0.502.242.13 0.97
Max drawdown, 5Y -97.6%-59.5%-63.9% -25.4%
From 52-week high -29.8%-9.7%-1.7% -1.2%
52-week high $26.25$110.94$27.68 $779.14
52-week low $11.79$50.69$10.92 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePRELNTHCBLL
P/E now vs peer median -3.6xmedian 29.6x 23.7xmedian 29.6x -15.7xmedian 29.6x
P/S now vs peer median 1.7xmedian 2.9x 4.2xmedian 2.9x 10.2xmedian 2.9x
EV/EBITDA now vs peer median -4.2xmedian 17.4x 16.5xmedian 17.4x -13.6xmedian 17.4x
P/FCF now vs peer median -6.0xmedian 22.3x 16.9xmedian 22.3x -19.0xmedian 22.3x
P/B now vs peer median 3.3xmedian 2.3x 5.0xmedian 2.3x 8.1xmedian 2.3x
PEG now vs peer median -0.07median 1.04 0.22median 1.04 —median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPRELNTHCBLL
Revenue $185.92M $1.56B $101.96M
Gross profit $88.89M $936.02M $90.65M
Operating income -$61.83M $302.34M -$69.97M
Net income -$71.99M $275.31M -$66.00M
Free cash flow -$51.49M $387.83M -$54.72M
R&D $4.11M $173.09M $22.95M
EPS (diluted) $-5.06 $4.08 $-1.74
Cash & equivalents $59.05M $593.30M $32.66M
Total debt – $571.05M $19.98M
Shares (diluted) 14.05M 67.52M 38.03M
Enterprise value $174.72M $4.70B $442.19M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPRELNTHCBLL
P/E -3.6x 23.7x -15.7x
P/FCF -6.0x 16.9x -19.0x
P/Operating cash flow -6.0x 15.8x -19.3x
P/S 1.7x 4.2x 10.2x
P/B 3.3x 5.0x 8.1x
P/Tangible book 3.3x 10.5x 8.1x
EV/EBITDA -4.2x 16.5x -13.6x
EV/EBIT -4.1x 21.5x -13.3x
EV/Revenue 1.4x 4.2x 9.1x
EV/FCF -4.9x 16.8x -17.0x
EV/Operating cash flow -4.9x 15.8x -17.2x
PEG (3Y EPS CAGR) -0.07 0.22 –

Growth

14 metrics
MetricPRELNTHCBLL
Revenue growth (1Y) 513.0% 2.3% 31.7%
Revenue CAGR (3Y) 115.5% 11.4% –
Gross profit growth (1Y) 413.6% -3.4% 33.4%
Gross profit CAGR (3Y) 127.9% 16.3% –
Operating income growth (1Y) -49.2% -30.9% -34.6%
Operating income CAGR (3Y) -1.9% 118.8% –
Net income growth (1Y) -60.1% 1.6% -33.6%
Net income CAGR (3Y) -16.5% 102.1% –
EPS growth (1Y) -28.5% 5.8% -27.5%
EPS CAGR (3Y) 52.8% 105.5% –
Operating cash flow growth (1Y) – -21.7% -44.3%
Operating cash flow CAGR (3Y) – 14.5% –
Free cash flow growth (1Y) – -10.1% -41.8%
Free cash flow CAGR (3Y) – 103.0% –

Profitability

14 metrics
MetricPRELNTHCBLL
Gross margin 47.8% 60.1% 88.9%
EBITDA margin -32.6% 25.4% -67.1%
Operating margin -33.3% 19.4% -68.6%
Pretax margin -24.2% 23.3% -64.7%
Net margin -38.2% 17.7% -64.7%
FCF margin -27.7% 24.9% -53.7%
Operating cash flow margin -27.7% 26.5% -53.0%
Return on equity -67.3% 21.8% -49.0%
Return on assets -43.8% 11.6% -38.3%
Return on invested capital – 12.5% –
Return on capital employed -48.3% 14.8% -45.1%
Asset turnover 1.1x 0.7x 0.6x
Cash conversion (OCF / net income) 0.7x 1.5x 0.8x
Stock comp / revenue 3.4% 5.0% 16.1%

Financial Health

11 metrics
MetricPRELNTHCBLL
Debt / assets – 23.6% 12.0%
Debt / equity – 0.4x 0.2x
Net debt / EBITDA – -0.1x 1.6x
Debt / FCF – 1.5x -0.4x
Liabilities / assets 39.5% 45.7% 22.9%
Equity / assets 60.5% 54.3% 77.1%
Interest coverage – 15.3x -38.6x
Current ratio 4.0x 3.1x 9.2x
Quick ratio 1.8x 2.8x 8.6x
Cash ratio 1.6x 1.8x 7.5x
Altman Z-score – 5.46 14.47

Shareholder Returns

7 metrics
MetricPRELNTHCBLL
Dividend yield – – –
Net buyback yield – 2.9% -0.6%
Shareholder yield 0.0% 2.9% -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPRELNTHCBLL
Forward P/E – 17.4xFY2026 –
EPS, next fiscal year $-3.42FY2026 $5.76FY2026 $-1.86FY2026
EPS growth, next FY – -5.3%FY2026 –
EPS growth, the year after – +4.2% –
Revenue, next fiscal year $234.43MFY2026 $1.57BFY2026 $118.32MFY2026
Revenue growth, next FY +153.7%FY2026 +1.8%FY2026 +32.9%FY2026
Revenue growth, the year after +65.3% +12.7% +21.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPRELNTHCBLL
Held by institutions 0.9% 100.0% 79.9%
Institutions holding 1 465 124
Change in shares held, QoQ – +3.4% +2.2%
Institutions buying 0 248 74
Institutions selling 0 142 36
Buyers to sellers – 1.75 2.06

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PRELNTHCBLL
PRE 1.00 0.09 0.11
LNTH 0.09 1.00 0.21
CBLL 0.11 0.21 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PRE, LNTH and CBLL?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Prenetics Global (PRE) $310.99M, Lantheus Holdings (LNTH) $6.54B, Ceribell (CBLL) $1.04B.

Which company is growing faster?

Prenetics Global (PRE) grew revenue fastest over the trailing twelve months: Prenetics Global (PRE) +513.0%, Lantheus Holdings (LNTH) +2.3%, Ceribell (CBLL) +31.7%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Prenetics Global (PRE) -38.2%, Lantheus Holdings (LNTH) 17.7%, Ceribell (CBLL) -64.7%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Prenetics Global (PRE) +40.9%, Lantheus Holdings (LNTH) +72.3%, Ceribell (CBLL) +111.2%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Prenetics Global (PRE) -30.7%/yr, Lantheus Holdings (LNTH) +34.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Prenetics Global (PRE) 81.0%, Lantheus Holdings (LNTH) 32.3%, Ceribell (CBLL) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PRE, LNTH and CBLL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.